A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

  • Interventional
  • Recruiting
  • NCT04106219
Eligibility Details Visit Clinicaltrials.gov

A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma

The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.

Gender
All

Age Group
2 Years to 21 Years

Accepting Healthy Volunteers?
No

Inclusion Criteria:

         - Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue.

         - Participants must be able to swallow capsules.

        Exclusion Criteria:

         - Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant.

         - Participants must not have untreated tumor that has spread to the brain or spinal cord.

         - Participants must not have a serious active disease other than neuroblastoma.

         - Participants must not have a condition affecting absorption.

         - Participants must not have had prior aurora kinase inhibitor exposure.

         - Participants must not have a known allergy to the study treatment.

         - Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.
  • Neuroblastoma

At a Glance

National Government IDNCT04106219

IRB#IRB19-1648

Lead SponsorEli Lilly and Company

Lead PhysicianAmi Desai

Collaborator(s)N/A

EligibilityAll
2 Years to 21 Years
Recruiting